is usually treated with anti-inflammatory agents and immunosuppressants, although a high percentage of patients do not respond to these conventional treatments and require TNF antagonists. In randomized clinical trials, TNF antagonists showed clear benefits over conventional treatments for inducing and maintaining clinical remission (CR), reducing the need for corticosteroids, and decreasing frequency of hospitalization and surgery in both CD and UC. [3] [4] [5] [6] [7] [8] [9] [10] However, despite the efficacy of TNF antagonists, over one-third of patients fail to respond to induction treatment (primary nonresponders), and therapy becomes ineffective with time in up to 50% of cases (secondary nonresponders). Therefore, it is critical to develop new approaches to optimize and improve the effectiveness of treatment. 11 Treatment fails for various reasons, but interindividual and intraindividual differences in the pharmacokinetics of anti-TNF drugs are a major cause of failure. ADL is administered subcutaneously, and its absorption seems to be through lymphatic drainage. It is eliminated mainly by proteolytic catabolism after receptor-mediated endocytosis in the reticuloendothelial system. 12 The main disadvantage of subcutaneous administration is that the fraction of dose absorbed is variable, leading to greater differences in pharmacokinetics between patients. Moreover, this route is often more immunogenic than intravenous administration, because processing of antigens through the skin is highly specialized. 13 The several factors that affect the pharmacokinetics of anti-TNF agents include concomitant use of immunosuppressants (decreases clearance), low albumin levels (increase clearance), high baseline C-reactive protein (CRP) levels (increase clearance), high baseline TNF levels (may increase clearance), high body surface area (may increase clearance), and sex (clearance increased in males). However, one of the most important factors is the development of anti-ADL antibodies (AAAs), which also increases the frequency of adverse events. 10 AAAs both neutralize the biological activity of the anti-TNF binding to specific idiotypes and accelerate drug clearance through the reticuloendothelial system by forming immunocomplexes. The development of AAAs is clinically significant because it eventually limits the effectiveness of the drug by decreasing serum levels. 14, 15 ADL has been used for over a decade, yet individualized dosing remains uncommon. Most patients are treated according to established protocols with fixed doses administered at fixed intervals. However, given the high interindividual variability in clearance, growing evidence of improved outcomes achieved by maintaining adequate serum drug concentrations has been reported. [16] [17] [18] The association between trough serum ADL concentrations and efficacy has been reported in retrospective and prospective studies, where low drug concentrations were associated with a poorer response. 17, 19 Karmiris et al 20 showed that lower serum ADL concentrations were present in patients with CD who discontinued therapy owing to loss of response and that AAAs affected serum trough concentrations. A post hoc analysis of the Karmiris trial found that the risk of AAA formation increased with lower early serum ADL concentration and, AAAs and ADL were strongly associated with higher future CRP level and discontinuation of ADL. 21 Roblin et al 22 reported that median ADL trough concentrations in patients with CD and UC in CR were much higher than in patients with active disease (6.0 versus 3.2 mg/mL, P ¼ 0.012) and higher in patients who achieved mucosal healing than in those who did not (6.5 versus 4.2 mg/mL, P , 0.005). Nevertheless, the ADL cutoff remains unclear. In the first published studies, the authors set it at 5 mg/mL, 18 but recent studies report that ADL cutoff levels in IBD could be above 8 mg/mL. [23] [24] [25] The objectives of this study were as follows: to investigate the association between random serum ADL levels, CR, and normalization of biochemical parameters; to examine clinical decision making in daily practice according to serum ADL levels; and to determine the cutoff value for successful dose reduction in patients with IBD treated with ADL.
MATERIAL AND METHODS

Study Design and Patients
We performed a prospective observational study of patients with IBD receiving long-term maintenance therapy with ADL. The study population comprised consecutive adult patients with CD or UC followed at the IBD Unit of La Fe Polytechnic University Hospital (Valencia, Spain) and treated with ADA for whom complete clinical documentation was available. All patients received induction with ADL (160 and 80 mg at weeks 0 and 2) and were maintained on either 40 mg every week or every other week. All ADL samples were drawn after patients had been receiving their maintenance dose for at least 12 weeks as routine clinical practice. Serum samples were obtained between March 2014 and December 2015. The inclusion criteria were age .15 years and diagnosis of CD or UC according to internationally accepted criteria. 26, 27 The exclusion criteria were ulcerative proctitis, therapy with ADL for perianal disease or extraintestinal manifestations, ileostomy, and short bowel syndrome.
Definitions and Input Variables
The demographic and clinical data recorded included age, sex, smoking status, date of diagnosis, disease behavior, location according to the Montreal classification, previous surgery, previous exposure to biologic drugs, use of concomitant medications, and details on ADL therapy (dose, time, and frequency). The Harvey-Bradshaw and partial Mayo/Mayo Score were recorded for patients with CD and UC, respectively. 28, 29 Biochemical data were also recorded as follows: albumin (g/dL), fecal calprotectin ([FC], ng/g), and CRP (mg/L). FC was determined in the Clinical Analysis Department using a quantitative enzyme-linked immunoassay (Calprest; Eurospital, Trieste, Italy) in a Best 2000 fully automated plate enzyme-linked immunosorbent assay (ELISA) analyzer. Ileocolonoscopy and/or magnetic resonance enterography results were collected only if they were performed at least 1 month before or after ADL levels were recorded.
Ileocolonoscopy was performed using an Olympus colonoscope, and magnetic resonance enterography examination was performed using a standardized clinical protocol on a 1.5-T or 3-T magnetic resonance scanner (GE Medical Systems, Milwaukee, WI).
Clinical response was determined based on the Harvey-Bradshaw Index in the case of CD and the partial Mayo Score in the case of UC. These scores are routinely recorded at each visit in our practice. (CR) was defined as a Harvey-Bradshaw Index #4 for patients with CD and as a partial Mayo Score #1 for patients with UC. Biochemical remission was defined as CRP ,5 mg/L and FC ,50 ng/g. Mucosal healing was defined as a Mayo score of 0 to 1 for UC or the disappearance of all ulcerations in patients with CD who had undergone colonoscopy.
The clinical practice decisions taken on the basis of serum ADL levels were as follows: no change (same dosage), intensification (40 or 80 mg every week), deintensification (40 mg every other week), change in treatment (switch to another anti-TNF drug or to a biologic agent with another mechanism of action), or discontinuation of treatment. Dose reduction was defined as successful when the patient remained in CR according to clinical activity index, without further dose intensification on, at least, the following 6 months; dose intensification was defined as successful when the patient's clinical status improved.
Measurement of Serum ADL Trough Concentration and AAAs
Serum samples were obtained just before injection of ADL (trough concentration). The sera were separated and handled according to standard operating procedures and stored at 2208C until analysis.
Serum ADL concentrations were determined using sandwich ELISA (Promonitor-ADL; Proteomika S.L., Derio, Spain), in which the microwell strips are precoated with anti-ADL human Fab. ADL in serum binds to the antibody, and a second horseradish peroxidase-labeled anti-ADL monoclonal antibody is added. Enzyme activity is measured by adding a chromogenic substrate and measuring color intensity.
AAA levels were determined using bridging ELISA (Promonitor-Anti-ADL; Proteomika S.L., distributed by Grifols S.A.), which detected free AAAs in serum. In this test, microwell strips are precoated with ADA. AAAs in serum bound to preimmobilized ADL and horseradish peroxidase-labeled ADL were added. 30 A per-event analysis was used to analyze ADL levels data. The Mann-Whitney test was used to compare continuous variables. Receiver operating characteristic (ROC) curves were constructed, and an area under the curve (AUC) analysis was performed for serum ADL levels. Cutoff values of serum ADL concentrations were determined with their sensitivity (Se), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) and according to the prevalence of responders in the sample. Logistic regression analysis was performed to determine the predictive factors associated with response.
Statistical Analyses
RESULTS
We collected data on 87 patients with IBD (16 with UC) who were receiving maintenance therapy with ADL. Median duration of therapy until determination of serum concentrations was 41.4 months (IQR: 32.8-53.6). Demographic data, diseaserelated data, and treatment characteristics are shown in Table 1 .
Data were available for 157 serum samples. The median for serum ADL levels in the study population was 8.4 mg/mL (IQR: 4.4-13.6). Almost all the patients had detectable levels, and serum ADL levels were undetectable in only 11 cases (7.0%). AAAs were detected in 7 cases (4.5%).
Serum ADL Levels, AAAs, and CR Serum ADL levels were associated with CR in patients with IBD (P , 0.001, Mann-Whitney test). The median serum ADL levels for patients in CR was 10.2 mg/mL (IQR: 5.3-14.8) compared with 6.0 mg/mL (IQR: 3.6-9.1) in patients with active disease (P , 0.001, Mann-Whitney test). In patients with UC, median serum ADL levels were 14.4 mg/mL (IQR: 10.0-20.0) for CR (partial Mayo Score #1) and 5.2 mg/mL (IQR: 1.4-9.2) for active disease (P ¼ 0.002, Mann-Whitney test). In patients with CD, median serum ADL levels were 9.2 mg/mL (IQR: 4.6-13.8) for CR (Harvey-Bradshaw Index ,5) and 6.0 mg/mL (IQR: 3.8-8.8) for active disease (P ¼ 0.009, Mann-Whitney test).
ROC curve analysis revealed a positive association between serum ADL levels and remission (AUC ¼ 0.68 [95% CI, 0.60-0.77]) (Fig. 1A) and showed a cutoff ADL concentration of 9.0 mg/mL for discrimination between patients in CR and patients with active disease (Se: 58.3%; Sp: 74.6%; PPV: 72.4%; NPV: 61.0%).
The association between serum ADA levels and CR was also explored using logistic regression (both forward and backward stepwise selection, P for inclusion ,0.05, P for exclusion .0.10) including serum ADL level $9.0 mg/mL, age, sex, weight, smoking status, previous infliximab treatment, CD/UC, concomitant corticosteroids, concomitant immunosuppression, previous surgery, and positive AAA titers. No differences on ADL concentrations were found between patients on concurrent immunosuppression 
Endoscopic and Radiological Remission
Endoscopy results coinciding with the determination of serum ADL levels were available for only 11 patients. Serum ADL levels were 4.8 mg/mL (IQR: 4.0-5.6) for patients in remission (n ¼ 2), 6.8 mg/mL (IQR: 5.0-8.6) for patients with moderate disease activity (n ¼ 5), and 5.8 mg/mL (IQR: 2.9-8.1) for patients with severe disease activity (n ¼ 4). No further calculations could be performed because of the low number of patients.
Magnetic resonance enterography coincided with determination of serum ADL levels in 18 patients, although activity data were available for only 11. Serum ADL levels for patients with low disease activity (9.0 mg/mL [IQR: 6.4-12.8], n ¼ 4) were higher than serum levels for patients with moderate disease activity (5.2 mg/mL [IQR: 1.2-9.2], n ¼ 4) or severe disease activity (5.8 mg/mL [IQR: 4.5-7.1], n ¼ 3). No further calculations could be performed because of the low number of patients.
Serum ADL Levels and Biochemical Remission
The median serum CRP value in our population was 2 mg/mL (IQR: 0.9-7.0). Serum ADL levels were associated with normalization of CRP (CRP , 5 mg/L). The median serum ADL concentration was 9.2 mg/mL (IQR: 5.2-14.4) for patients with a normal CRP value and 5.2 mg/mL (IQR: 2.0-9.2) for patients with a high CRP value (P ¼ 0.002, Mann-Whitney test). ROC curve analysis discriminated slightly between patients whose CRP levels had returned to normal and those whose levels did not (AUC ¼ 0.68 [95% CI, 0.59-0.76]) (Fig. 1B) , with a cutoff ADL level of 6.6 mg/mL (Se: 65.6%; Sp: 60.0%; PPV: 81.8%; NPV: 38.9%).
The median FC value in this population was 130.0 ng/g (52.0-433.0). No association with normalization of FC (#50 ng/g) was found. The serum ADL level was 11.0 mg/mL (IQR: 5.7-14.8) for patients with a normal FC value and 8.4 mg/mL (IQR: 4.3-13.2) for patients with FC .50 ng/g (P ¼ 0.165, Mann-Whitney). ROC curve analysis revealed an AUC of 0.58 (95% CI, 0.47-0.68).
No associations with the presence of AAAs were established because these antibodies were detected only in 7 cases.
Clinical Decisions Based on Serum ADL Levels
We analyzed the clinical decisions taken on the basis of serum ADL levels according to the cutoff values described in previous studies (8 mg/mL). Table 2 describes patients' drug levels according to the clinical decision taken. The same dosage was maintained when the median ADL level was 7.8 mg/mL (n ¼ 90 serum samples), whereas treatment was intensified when median ADL levels were 3.2 mg/mL (n ¼ 8) and deintensified (n ¼ 24) in patients with 15.6 mg/mL. Other decisions taken were switching to another anti-TNF drug (n ¼ 8), switching to a non-anti-TNF drug (n ¼ 2), discontinuation of treatment (n ¼ 7), and combination with another immunosuppressant (n ¼ 3). No associations were found between combined immunosuppression and tolerating de-escalation (P ¼ 0.074, 2-sided Fisher's test). And there were no differences in ADL levels after de-escalation among patients in whom de-escalation was successful and in whom it was not. Median 12.4 mg/mL (IQR: 8.8-14.8) in those who continued in remission versus 13.2 mg/mL (IQR: 5.6-16.4) among those who failed (P ¼ 0.711 K-W test). In 35 of the 87 patients included, changes in treatment were made according to drug levels. Changes in treatment according to drug levels were successful in 71.4% of cases (Fig. 2) . The mean time between 2 consecutive serum samples to decide if deintensification had been successful was 7.4 months (95% CI, 5.3-9.5). An ROC curve was created for ADL levels and successful deintensification and compared with the group in which no dose changes were required. The AUC was 0.88 (95% CI, 0.81-0.95; P , 0.001) (Fig. 3) , with a cutoff value of 12.2 mg/mL for successful deintensification (Se: 85.7%; Sp: 82.2%; PPV: 43.0%; NPV: 97.4%). Basal levels were 16.2 mg/mL (IQR: 13.9-18.7) and changed to 11.2 mg/mL (IQR: 8.6-13.5) over a 6-month period of clinical follow-up.
DISCUSSION
Therapeutic drug monitoring (drug levels and AAA) for patients receiving ADL has rapidly gained acceptance as a1 useful tool for managing patients with IBD. It provides additional information that can aid in clinical decision making (e.g., whether to intensify or deintensify treatment or to switch to another anti-TNF drug or to a biologic with another mechanism of action). The main objective of treatment today is for the patient to achieve mucosal healing or even histological healing. However, the therapeutic level of ADL remains unknown. In this study, we found that serum ADL levels were associated with CR and normalization of inflammatory markers in patients with IBD with long-term ADL therapy. A cutoff ADL concentration of 9 mg/mL was found for discrimination between patients in CR and patients with active disease. These results are consistent with those described in a retrospective study of 67 patients with IBD treated with ADL in which the authors proposed that serum levels of 8 to 12 mg/mL are required to achieve mucosal healing in 80% to 90% of patients, and that this range could be considered a "therapeutic window." 23 In a crosssectional study of 66 patients with IBD, the ADL level that was best associated with histologic healing was 7.8 mg/mL, and the ADL level that was best associated with endoscopic healing was 7.5 mg/mL. 24 Furthermore, our results were similar to those reported in the recent prospective study by Bodini et al, 25 who evaluated 23 infliximab-naive patients with CD who achieved CR after induction and maintenance treatment with ADL. The authors found significantly different serum ADL trough levels in patients in remission (10.1 mg/mL) compared with those with mild disease (7.4 mg/mL) and those with moderate/severe disease (4.5 mg/mL).
We also found that serum ADL levels were associated with normalization of CRP and FC values. As in other studies, lower ADL levels correlated with higher titers of CRP. 24, 31 On the other hand, no statistically significant association was found between FC #50 mg/g and serum ADL levels, although drug levels were higher for patients with normal FC levels. It was recently suggested that FC levels should be higher than 50 mg/g to differentiate between remission and active disease. 32, 33 In this sense, Zittan et al 34 assessed whether FC levels correlated with the degree of endoscopic mucosal inflammation and the degree of histologic mucosal inflammation in 58 patients with IBD. The authors demonstrated that low FC (,100 mg/g) was highly correlated with clinical, endoscopic, and histological remission.
Roblin et al 35 reported that ADL cutoff values differed depending on the criterion chosen for response (clinical or biochemical). The cutoff value for normalization of CRP was much lower than that of CR, as in our results.
We assessed the clinical decisions taken according to serum ADL levels in daily practice. Changes in ADL dosage based on serum drug levels and clinical course were successful in most of the patients analyzed. On the one hand, deintensification of ADL was the most frequent change, with a cutoff value for successful deintensification of 12.2 mg/mL, which differs from the cutoff value for CR. This value is important because it reveals a gap between the optimal drug level for maintenance of CR and the drug level from which deintensification may be performed. There were no differences in ADL levels after de-escalation in patients in whom de-escalation was successful and in whom it was not. It is possible that a group of patients, as yet unidentified, will need higher ADL levels. On the other hand, the 2 groups (switch to anti-TNF or non-anti-TNF) correspond to a loss of clinical response (secondary failure), and the change in treatment was made in the clinical judgment of the physician, even though ADL levels were adequate.
Our study is subject to a series of limitations. First, because ileocolonoscopy was not performed to assess mucosal lesions in all patients, we did not find a correlation between remission endoscopy and serum ADL levels or clinical and biochemical remission. Another limitation was that remission was evaluated using the Harvey-Bradshaw Index for CD and partial Mayo Score for UC. Both are indices of clinical activity. Furthermore, because ADL was combined with immunomodulators in 44% of patients, the frequency of immunogenicity could be lower in this group because they were receiving combination therapy. This percentage is slightly higher than those reported in other studies (between 28% and 33%). 24, 25 It is important to note that the lower frequency of immunogenicity detected in this study is due to the fact that the ELISA technique available in our institution is only able to detect free AAAs. Drug interference is the main limitation of this assay: residual or low drug levels may interfere by competitive inhibition or by forming immune complexes. Therefore, measurement of AAA titers in complex with the drug is not possible, and interference by the drug can cause false negatives in the AAA assay. 36 It is also plausible that some patients with AAA titers were so reduced in patients with low drug concentrations that we were unable to detect them. Another reason that could justify the low frequency of AAA in this study is that therapeutic drug monitoring was performed after a median of almost 2 years of treatment with ADL.
In conclusion, serum ADL levels were associated with CR and normalization of CRP in patients with IBD, with a cutoff ADL concentration of 9 and 9.2 mg/mL, respectively. Thus, our results strongly suggest that 9 mg/mL is an appropriate cutoff value for discrimination between patients in CR and those with active disease. Furthermore, ours is the first prospective study to evaluate clinical decisions taken in daily practice based on serum ADL levels and to determine a cutoff value (12.2 mg/mL) for successful dose reduction in patients with IBD treated with ADL. Further longer-term prospective studies are needed to replicate our findings. Such studies will enable us to better understand the decisions taken in clinical practice, namely, whether to intensify or deintensify treatment or switch to another anti-TNF agent or biologic with different mechanism of action.
